Therapy News and Research

RSS

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.

17 Nov 2009

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.

17 Nov 2009

Program for childhood cancer survivors to quit smoking

As smokers nationwide struggle to quit the habit, St. Jude Children's Research Hospital is offering assistance to those childhood cancer survivors who need help with smoking cessation.

17 Nov 2009

Antidepressant drug is effective in treating women with low libido

The drug flibanserin, which was originally created as an antidepressant, is effective in treating women with low libido, pooled results from three separate clinical trials have found.

17 Nov 2009

FDA approves NeurogesX's Qutenza patch for postherpetic neuralgia treatment

NeurogesX, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Qutenza(TM) (capsaicin) 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia (PHN), the nerve pain which can follow shingles.

17 Nov 2009

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

PPD, Inc. today announced it has entered an agreement with Janssen Pharmaceutica N.V. to develop and commercialize two Phase II-ready therapeutic compounds, one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin structure and respiratory infections.

17 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

HDAC inhibitors: New therapy for treating breast cancer

A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself, researchers say.

17 Nov 2009

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year.

17 Nov 2009

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

A protein long thought to be a secondary regulator in the heart's response to stressors like hypertension actually appears to be a primary regulator according to researchers from the Center for Translational Medicine at Thomas Jefferson University.

17 Nov 2009

Sudden cardiac death more predictable in men than women

A woman who suffers sudden cardiac arrest is significantly less likely than a man to exhibit the decrease in the heart's pumping ability that is widely recognized as a precursor, says a new study in the Nov. 24 Journal of the American College of Cardiology.

17 Nov 2009

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

17 Nov 2009

Pet therapy can have a positive effect on patients’ physical and psychosocial well being

Adults who use pet therapy while recovering from total joint-replacement surgery require 50 percent less pain medication than those who do not. These findings were presented at the 18th Annual Conference of the International Society of Anthrozoology and the First Human Animal Interaction Conference (HAI) in Kansas City, Mo.

17 Nov 2009

Stem cell therapy to treat heart, lung and vascular diseases show positive results

A Florida cardiologist is using stem cell therapy to treat patients who suffer from a range of heart, lung and vascular illnesses. The results have been extraordinary.

16 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

Migraine headaches linked with increased risk of common kind of stroke

Pooling results from 21 studies, involving 622,381 men and women, researchers at Johns Hopkins have affirmed that migraine headaches are associated with more than twofold higher chances of the most common kind of stroke: those occurring when blood supply to the brain is suddenly cut off by the buildup of plaque or a blood clot.

16 Nov 2009

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.

16 Nov 2009

Erbitux recognized as one of the major clinical cancer advances of 2009

The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

PGxHealth, a division of Clinical Data, Inc., today announced the launch of its genetic test for familial Dilated Cardiomyopathy, an inherited heart disease which is the leading cause of heart transplants and a possible cause of sudden cardiac death.

16 Nov 2009

Therapy News and Research

ThromboGenics and BioInvent International present phase I results of novel anti-cancer monoclonal antibody

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

Program for childhood cancer survivors to quit smoking

Antidepressant drug is effective in treating women with low libido

FDA approves NeurogesX's Qutenza patch for postherpetic neuralgia treatment

PPD, Janssen Pharmaceutica to develop therapeutic compounds for IBS and bacterial infections

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

HDAC inhibitors: New therapy for treating breast cancer

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

Sudden cardiac death more predictable in men than women

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Pet therapy can have a positive effect on patients’ physical and psychosocial well being

Stem cell therapy to treat heart, lung and vascular diseases show positive results

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Migraine headaches linked with increased risk of common kind of stroke

Onyx Pharmaceuticals acquires Proteolix

Erbitux recognized as one of the major clinical cancer advances of 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Genetic test for familial Dilated Cardiomyopathy launched by PGxHealth

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News